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EDITORIAL
In view of the recent problems that referees are faced with, in papers on in vivo
carcinogenesis, the Editors have asked Mr Richard Peto, Department of the Regius
Professor of Medicine, the Radcliffe Infirmary, Oxford, to prepare the following
" editorial " notes. Mr Peto would be glad to correspond with anybody who has
difficulty in using them. The British Journal of Cancer does not, of course, wish to
force the use of these methods on all experimentalists; we merely wish to recommend
them to those who are in doubt as to how to describe their experimental results.
GUIDELINES ON THE ANALYSIS OF TUMOUR RATES AND DEATH RATES
IN EXPERIMENTAL ANIMALS
R. PETO
From the Departnment of the Regius Professor of Medicine, The Radcliffe Inftrnmary, Oxford
If a group of experimental animals is
exposed to a carcinogenic treatment, the
actual number of (for example) hepatomata
that will be discovered depends not only on
the carcinogenic force of the treatment but
also on the mortality that occurs among the
animals from causes other than hepatomata.
The connection between intercurrent death
rates andthe hepatoma crop is subtle, since (a)
death causes necropsy of the dead animal to
occur, and if an otherwise unsuspected
hepatoma is discovered at necropsy, then the
death of the animal caused the discovery of
that hepatoma; (b) if an animal who would
have developed a hepatoma at a certain time
dies (of some other tumour, or of worms,
perhaps) before that hepatoma is big enough
to be found, then death has prevented the
discovery of that hepatoma.
Animal experiinents reported in the
BritishJournalofCancerinwhichthenumbers
of tumours resulting from different carcino-
genic regimens are compared must be
described in such a way that estimates of the
relative carcinogenic forces of the different
regimens are not biased by heterogeneous
mortality patterns in the different treatment
groups. Thefollowingsuggestions mayprove
helpful in achieving this. These suggested
methods require only that a sharp distinction
be made between " incidental " (discovered at
the necropsy of an animal which died of some-
thing else) tumours and " non-incidental"
(other) tumours.
A pos8ible method ofdealing with difficulty (a):
Comparisons ofcrops of " incidental " tumours
Divide the experimental lifetime of the
animals up into periods (each perhaps of a
few weeks' duration) which are short enough
for it to be reasonable to compare all the
necropsies that take place in one period with
each other. Now produce a table of all the
necropsies of animals which died from causes
other than a hepatoma and in which no
hepatoma had been found before their death
(including animals which were deliberately
sacrificed while still apparently healthy),
giving the numbers of these necropsies at
which hepatomata were discovered.
TABLE I.-Numbers of ' Incidental " Hepatomata Discovered at Necropsy in a
Hypothetical 3-group Experiment
Period 1 Period 2 Period 3 Period 4 Period 5 Period 6 Treatment (0-4 weeks) (5-9 weeks) (10-14 weeks) (15-19 weeks) (20-24 weeks) (25-29 weeks)
A 0/4 1/5 2/7 2/10 3/9 1/2 B 0/7 0/5 0/8 1/12 1/8 0/3 C 0/12 1/10 5/15 11/28 3/3 0/0
Key: a/b: b = No. of necropsies of animals which did not have a hepatoma diagnose(l before death and
which did not die of a hepatoma;
a = No. of these necropsies at which hepatomata were foun(l.
8TABLE II.-Expected Numbers of " Incidental " Hepatomatafrom the Data in
Table I, Assuming that Treatments A, B and C are Equally Hepatocarcinogenic
Period 1 Period 2 Period 3 Period 4 Period 5 Period 6
Treatment (0-4 weeks) (5-9 weeks) (10-14 weeks) (15-19 weeks) (20-24 weeks) (25-29 weeks)
A 0-00 0*50 1-63 2-80 3-15 0 40
B 0 00 0 50 1-87 3-36 2-80 0-60
C 0 00 1-00 3*50 7-84 1-05 0.00
(The expected numbers in Table II are derived from the observed numbers in Table I by using the fact
that ifA, B and C are equally hepatocarcinogenic then all such necropsies in any one period are equally likely
to reveal hepatomata. Check the calculations for periods 2 and 6 if this is not clear.)
Comparison ofthe overall observed andthe
overall expected tumour crops, as in Table III,
for the three different treatment groups is
now valid no matter what differences between
the necropsy rates in the three groups existed.
TABLE III.-Sumsfor All Periods Together
of Observed and Expected Numbers of
" Incidental " Hepatomata, from Tables
I and II
Overall Overall
Treatment observed expected
A 9 8-48
B 2 9-13
C 20 13-39
Ratio
1-06
0-22
1-49
As a formal statistical test of whether
such extreme differences as those found in
Table III could arise by chance alone ifthere
was no difference between the hepatocarcino-
genicity oftreatments A, B andC, we examine
the statistic
(9 - 8-48)2+ (2 9- 13)2+(20 -13.39)2 = 8-86
8.48 9113-39
The probability of getting differences
between observed and expected numbers as
extreme as those in Table III by chance alone
can be shown to be approximately the prob-
ability that the chi-squared distribution on
2 degrees of freedom should exceed 8-86, i.e.
about 0.01. (The degrees of freedom for the
chi-squaredisalways one less thanthenumber
of treatments being compared with each
other.)
A possible method ofdealingwith difficulty (b):
Comparisons of crops of " non-incidental
tumours
In this section tumours which are either
detected during life or cause death are discus-
sed. The method used is very similar to that
used in the previous section, in that the
period of the experiment is divided up into
sub-periods and in that we compare the treat-
ment groups with each other entirely within
single sub-periods, but in, this case the
appropriate sub-periods $ire much finer
(generally of no more than one week) and the
denominator is " all animals alive at the
beginning of the sub-period ".
A table of overall observed and overall
expected tumours is then abstracted, and
statistical analysis is similar to that following
Table III.
Again, a chi-squared test can be used
which is similar to that described following
Table III. Finally, summation ofTables III
and VI allows the dependence of the total
TABLE IV.-Hepatomata Diagnosed during Life or Causing Death in a Hypothetical
3-group Experiment
Treatment Week 0 Week 1 Week 2 ... Week 15 Week 16 ...
A 0/50 0/48 0/47 ... 1/30 0/28
B 0/50 0/49 0/45 ... 0/28 0/27 ...
C 0/75 0/71 0/68 ... 3/29 1/21 ...
Key: a/b: b = No. ofanimals still alive and without a diagnosed hepatoma at the beginning of the week;
a = No. of these animals dying of hepatomata or having a hepatoma diagnosed during the
week.
(The data of Table IV may be displayed by means of a cumulative-incidence grap'i. The " incidence"
in Group C in Week 15 is 3/29 = 0-103 and in Week 16 it is 1/21 = 0-048. The cumulative incidence for
Group C by the end of a particular week is the sum ofall the separate weekly incidences in Group C up to and
including that week. Graphs of the weekly cumulative incidences in the 3 treatment groups describe the
cancer crops in those groups visually, and are not biased by mortality from other causes.)
102 EDITORIALTABLE V.--Expected " Non-incidental " Hepatoma Crops from Data in Table IVT,
Assumting that Treatments A, B and C are Equally Hepatocarcinogenic
Treatment Week 0 Week 1 Week 2 . . . Week 15 Week 16 A 0.00 0.00 0.00 ... 1-379 0-368 ...
B 0-00 0-00 0-00 ... 1-287 0 355 ...
C 0 00 0.00 0 00 ... 1-333 0-276 ...
(The expectecl numbers in Table V are (lerived from the fact that if A, B and C are eqtually hepato- carcinogenic then all the animals alive an(d without a hepatoma at the beginning of a particuilar week are equally likely to develop a hepatoma during that week.)
TABLE VI. Sums for All Periods Together
of Observed and Expected Numbers of
Hepatomata Diagnosed invivo orCausing
Death
Overall Oveirall
Treatment observed expectecl Ratio
A
B
C
14
3
25
14-08
15-97
11 *95
0o99
0*19
2-09
TABLE VII. Total Crop of Hepatomata,
However Detected
No. of
animals
with
Treatment heXpatomata
A
B
C
23
5
45
Expected
no. with
hepatomata
22 - 56
25-10
25- 34
crop of hepatomata on treatment to be
assessed.
Again, a chi-squared test can be used on
this table which is similar to that described
following Table III.
NOTES
1. In Xeporting a statistical analysis ofthis
type, tables such as II and V should be omit-
ted from the published account of the experi-
ment and tables such as IV should be abbrevi-
ated by grouping the weeks as in Table I
(although calculation of Tables IT and VI
should be from the extended version of
Table IV).
2. Statistical analyses of this type are
used merely to find out whether it is plausible
to suppose all ofthe different treatments to be
of similar carcinogenic potency. In other
words, they test whether one group of animals
has significantly more cancers than another
group, but they may not describe the pattern
of incidence in a particular group at all wNell.
Description of the cancers in a group of
animals often requires different statistical
techniques, chief among which for non-
incidental tumours isthe "life-table "method.
(This is also known as the actuarial method,
and is equivalent to the cumulative-incidence
method described below Table IV. Life-table,
actuarial or cumulative-incidence graphs should not be used for significance testing.)
3. The estimation of dose/response rela-
tionships may require the fit of statistical
models: if so, care should be taken to fit
biologically plausible models (which may exclude the lognormal and normal or probit). Tests of significance should preferably not
assume particular statistical models.
4. The " mean latency " of a particular
cancer is so strongly dependent on the pattern of deaths from other causes that unless most
of the test animals get that particular cancer,
the ' mean latency" should only be used
extremely cautiously, if at all, in describing
the results of an experiment.
5. One animal can only contribute one
tumour to the '"observed" number of
tumours inthe group itbelongs to: subsequent
tumours on that animal are ignored, and the
animal itselfis excluded from consideration at
later times even ifit remains alive. Ifmulti-
plicity oftumours within particular animals is
of prime interest, different significance tests
must be devised.
6. The method of Tables I-VI can only
be applied if a clear distinction has been made
at the time the data are collected betwveen
tumours which are completely incidental, in
the sense that they are only detected because
death for some other reason has caused the
animal to be examined, and other tumours.
Malignant tumours wThich would eventually
prove fatal may be " incidental " tumours in
this sense if a random kill is performed before
they are fully developed, while a benign
tumour which blocks a vital organ may prove
fatal and so not be "' incidental ". The dis-
tinction between " incidental " and other
tumours is not necessarily of much biological
significance: it merely indicates how the
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tumour wras detected and hence whether the
statistical methods of Tables I, II and III or
the statistical methods ofTables IV, V and VI
should be used. All skin tumours, whether
benign or malignant, and almost all mammary
tumours, will be ' non-incidental ".
7. In Tables I-VII, treatments A, B and
C could, of course, be different dose levels of
the same substance. If this is so, the most
sensitive test of whether the substance has
any carcinogenic effect may be to pool all the
groups except the highest dose group, and to
compare two groups only: H, the highest dose
group, with L, the pooled lower dose and
control groups.
8. If the relationship between the ' non-
incidental" cancer crops in the different
treatment groups is governed by a Weibull
distribution (which is often the case), then no
other statistical method can be more sensitive
for detecting small differences betwreen the
carcinogenic forces ofdifferenttreatmentsthan
the comparison of the observed and expected
numbers oftumours in those groups.
REFERENCES TO THE STATISTICAL
LITERATURE
The text so far has been self-contained
and should enable experimentalists toperform
valid statistical significance tests and, per-
haps, to illustrate their results by cumulative-
incidence graphs with little or no need for
statistical advice. In most experiments,
these few techniques will be sufficient to get
everything possible out of the data. How-
ever, more complicated techniques may be
needed for the analysis of large or complex
experiments and statistical advice will then
be required. The following five statistical
references may be of use to statisticians who
are thus consulted. Although their content
is outside the scope of this paper (which, it is
hoped, will be read by experimentalists as
well as by statisticians), it often happens
that experimentalists consult statisticians
who have not previously analysed many
carcinogenesis experiments. If this happens,
it may be useful for the experimentalist to be
able to direct the attention of the statistician
to the following descriptions of the contents
of these five references. It is perfectly
possible to choose not to use any of them in
detailed studies of carcinogenesis data, but it
is probably unwise for statisticians to
undertake such studies in ignorance of the
contents of all of them.
(1) Statements such as 'P < 0*04" derived by taking a table of observed and
expected numbers of tumours, calculating E(O-E)2/E and taking its distribution to be
chi-squared, are always justified. However,
if instead the variances and covariances of
the (O-E) values for each treatment group
are calculated and are used to calculate a
chi-square by matrix inversion, it is some-
times possible to refine such statements (e.g.
to P <003 or P <002). A paper which
gives a cook-book description of howN this
may be done for data such as those in
Table VI above on non-incidental tumours is
Peto, R. and Pike, M. C. (1973). Conserva-
tism of the Approximation (O- E)2/E in
the Logrank Test for Survival Data or,
Tumour Incidence Data. Biometrics, 29,
579-584. This paper can easily be altered to
be a cook-book for data such as those in
Table III above on incidental tumours if the
definitions on p. 580 of it are altered so that
Rk is the number of necropsies in period k, dk is the number of these Rk necropsies at
which incidental tumours were discovered
and °,k = 0 if dk = 0. (Variances and
covariances for Table VII would be obtained
by summation.) These exact variances
should be calculated and used when the
pattern ofmortality in different groups is very markedly different, as the crude chi-square
may then be conservative.
(2) The " life-table " (also called the
actuarial ") method has sometimes been
used as an alternative to the "cumulative-
incidence " method described after Table IV.
The two methods are equally clear in the way they illustrate the real pattern of occurrence
of non-incidental cancers independently of
the effects of whatever other causes of death
the experimental animals may be being lost
to. Experimentalists who wish to use the
life-table ratherthanthecumulative-incidence
method to illustrate their data will find an
account ofit in: Pike, M. C. and Roe, F. J. C.
(1963). An Actuarial Method of Analysis of
an Experiment in Two-stage Carcinogenesis.
Br. J. Cancer, 17, 605-610. However, the
discussion in that paper of tests of
significance between life-tables should be
ignored.
(3) No method as natural as the cumula-
tive-incidence method or the life-table method
exists to produce from data on incidental
tumours a graph which estimates the pre-
valence of undetected tumours among theEDITORIAL
surviving animals at various ages. The
simplest graphical method is to plot the
proportions of incidental tumours discovered
among each period of necropsies (or to
calculate a moving average" of the pro-
portions in adjacent periods). This is only
satisfactory if there are many necropsies in
each period. However, although methods
do exist for constructing life-table analogues
from data on incidental tumours (Jl R.
statist. Soc. C (1973), 22, 86-91), they are
computationally far too complex for routine
use, especially since all that is finally w-anted
from them is an illustration.
(4) In pure strains of experimental
animals, the relationship between the crop of
non-incidental " cancers and the lifelong
rate of dosage of a carcinogen may be
governed by the so-called ' Weibull" distri-
bution. A paper wN,hich gives reasons hy
this may be true is: Peto, R., Lee, P. N. and
Paige, W. S. (1972). Statistical Analysis of
the Bioassay of Continuous Carcinogens.
Br. J. Cancer, 26. 258-261. The arguments
of this paper should be considered before
deciding how to describe particular dose/
response relationships mathematically.
(5) A paper on how to fit Weibull distri-
butions to animal data on non-incidental
cancers is: Peto, R. and Lee, P. N. (1973).
Weibull Distributions for Continuous-carci-
nogenesis Experiments. Biomnetrics, 29, 457-
470. This paper describes ho-w methods
analogous to multiple regression may be used
to predict cancer crops: however, the methods
are laborious, and should generally only be
used to quantify relationships which are
qualitatively obvious. The methods will
usually add little or nothing to the under-
standing of small amounts of data or of
wAeak or erratic relationships. An analogous
method of multiple regression ", about
Mwhich similar reservations apply, has recently
been discovered by D. R. Cox. At the
expense of some extra computing, Cox's
multiple regression method avoids the
ass8uaption of the Weibull family wNhile still
being fully efficient if the Weibull family
actually is appropriate. The original paper
describing Cox's method is complex, and
pp. 467-469 of the above Biometrics paper
sets out more simply those parts of Cox's
wAork which are relevant to animal carcino-
genenesis.
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